6 active not recruiting, 2 completed, 1 terminated, 1 withdrawn. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 6, Completed 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow BAY 1895344: new trials by email Literature Review of BAY 1895344 trials Research Report on BAY 1895344
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Copanlisib, Elimusertib - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-22 | 2022-05-27 | |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2021-08-13 | 2026-08-21 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Elimusertib (BAY1895344), Niraparib - Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer | Phase 1 | Terminated | Bayer | 14 | 2020-02-26 | 2023-12-21 |
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors | Phase 1 | Completed | Bayer | 56 | 2019-09-30 | 2024-04-02 |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Elimusertib (BAY1895344) - Advanced Solid Tumor, Non-Hodgkin's Lymphoma | Phase 1 | Completed | Bayer | 229 | 2017-07-06 | 2023-10-11 |
Ovarian Neoplasms (3) · Lung Neoplasms (2) · Lymphoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Ataxia Telangiectasia (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
National Cancer Institute (NCI) (6) · Bayer (3) · M.D. Anderson Cancer Center (1)
United States (9) · Canada (3) · Switzerland (2) · United Kingdom (2) · China (1) · Germany (1) · Japan (1) · Singapore (1) · Spain (1)
James M Cleary (1) · Liza C Villaruz (1) · Mamta Parikh (1) · Michael V Ortiz (1) · Thatcher Heumann (1) · Timothy A Yap, MD (1) · Yvonne M Mowery (1)
PMID 32502336, PMID 34904813, PMID 39841295
2018 (2), UM1CA186690 (2), 2016 (1), UM1CA186689 (1), UM1CA186709 (1), UM1CA186717 (1), UM1CA228823 (1)